“We are highly encouraged by our Phase 2 results with EloraTZP.”
The short answer: Lilly has registered its first two Phase 3 trials of EloraTZP, a single shot that combines the amylin drug eloralintide with tirzepatide (the drug in Zepbound).
They’re called AMPLIFY-1 and AMPLIFY-2, they last about two years, and they aren’t expected to finish until around the end of 2029. That puts EloraTZP years away from pharmacies.
In this post you’ll learn what the AMPLIFY trials will test, why one of them has no placebo at all, and when EloraTZP could realistically reach patients. About 5 minutes.
A New Trial Listing Is Not a New Drug
The moment a big Phase 3 trial appears on ClinicalTrials.gov, the internet gets excited. “EloraTZP is coming!”
It is. Slowly. A trial listing means the race has a starting line, not a finish.
That doesn’t mean it’s out next year. Phase 3 is the longest, most expensive part of a drug’s life, and these trials are long even by Phase 3 standards.
Action item: When you see “Phase 3 trial posted,” look for one date: the estimated completion. That’s the earliest the real answer can arrive.
Quick Refresher: What Is EloraTZP?
EloraTZP pairs two drugs in one weekly shot:
- Eloralintide copies amylin, a fullness hormone your pancreas releases with insulin.
- Tirzepatide is the drug in Zepbound and Mounjaro, which works on GLP-1 and GIP.
In its Phase 2 trial in people with type 2 diabetes, the top dose led to 23.3% weight loss at 48 weeks, versus 14.8% on tirzepatide alone. But up to 27% of people on some combo doses quit because of side effects. I broke down those results in Retatrutide vs EloraTZP.
Action item: Remember the one-liner: EloraTZP is “Zepbound plus amylin” in a single shot.
AMPLIFY-1: The Big Trial in People Without Diabetes
The registry lists AMPLIFY-1 as a Phase 3 study of the EloraTZP co-formulation in adults with obesity without type 2 diabetes. It compares EloraTZP with tirzepatide, eloralintide, and placebo. Participation lasts about two years. As of its October 19, 2026 update, it was not yet recruiting, per ClinicalTrials.gov.
According to a summary of the listings by trial watcher @JCanNuSH on X, AMPLIFY-1 plans about 2,100 participants across 8 arms: five EloraTZP doses, eloralintide alone, tirzepatide alone, and placebo, with about 100 weeks of treatment.
Five doses is unusual. It suggests Lilly wants to map the trade-off between weight loss and side effects carefully, which was the weak spot in Phase 2.
Action item: When results come, look past the top dose. A middle dose with far fewer dropouts may be the one most people actually use.
AMPLIFY-2: A Head-to-Head With Zepbound, No Placebo
AMPLIFY-2 is the type 2 diabetes trial (search EloraTZP on ClinicalTrials.gov). Per the same summary, it plans about 1,000 participants and just two arms: EloraTZP versus tirzepatide alone. No placebo.
That’s a confident design. Beating placebo is easy for these drugs. Beating tirzepatide, already one of the strongest approved weight-loss drugs, is the real test. If EloraTZP wins clearly, it earns a place. If it only edges ahead with more side effects, that’s a harder sell.
Novo Nordisk’s amylin combo, CagriSema, lost its own head-to-head against tirzepatide in 2026. EloraTZP is walking into the same arena.
Action item: If you have type 2 diabetes, AMPLIFY-2 is the trial to watch. It answers your real question: is it better than what I can get now?
When Could EloraTZP Reach Pharmacies?
Here’s the honest math. Per the listings summary, both trials are estimated to finish around the end of 2029. Then Lilly analyzes results, files with the FDA, and waits for a review that usually takes about a year.
That makes 2030 or later the realistic earliest window. It’s our estimate, not Lilly’s, and fast-track programs could shorten it a little. Listing dates also move.
In the meantime, eloralintide alone is already in its own Phase 3 trials, and retatrutide is much closer, with an FDA filing planned for early 2027.
Action item: If you’re deciding about treatment now, decide based on what’s approved today. EloraTZP is a 2030s option.
Quick Answers
What is AMPLIFY-1? A Phase 3 trial of EloraTZP in adults with obesity without type 2 diabetes, comparing it with eloralintide, tirzepatide, and placebo over about two years.
What is AMPLIFY-2? A Phase 3 trial in adults with obesity and type 2 diabetes comparing EloraTZP directly with tirzepatide, with no placebo group.
When will EloraTZP be available? Not before the trials finish, estimated around the end of 2029. A realistic earliest approval is 2030 or later.
Can I join the AMPLIFY trials? As of October 2026, AMPLIFY-1 was listed as not yet recruiting. Check ClinicalTrials.gov for sites near you once it opens.
How much weight did EloraTZP cause in earlier trials? Up to 23.3% at 48 weeks in people with type 2 diabetes in Phase 2, versus 14.8% on tirzepatide alone.
What This Means for You
✅ You know EloraTZP is “Zepbound plus amylin” in one shot
✅ You know AMPLIFY-1 tests five doses against three comparisons
✅ You know AMPLIFY-2 is a straight fight with tirzepatide
✅ You know the realistic timeline is 2030 or later
✅ You’ll judge results by dropouts, not just the top number
The 5-Minute Version (Screenshot This)
- News: Lilly registered two Phase 3 EloraTZP trials, AMPLIFY-1 and AMPLIFY-2, in October 2026.
- AMPLIFY-1: no diabetes, about 2,100 people, five EloraTZP doses vs eloralintide, tirzepatide, and placebo.
- AMPLIFY-2: type 2 diabetes, about 1,000 people, EloraTZP vs tirzepatide, no placebo.
- Length: about two years each; estimated completion around the end of 2029.
- Availability: realistically 2030 or later.
Conclusion
EloraTZP’s Phase 3 trials are big, long, and ambitious, including a no-placebo showdown with tirzepatide. That’s a sign of confidence. It’s also a sign that real answers are years away.
Your one action today: if you’re weighing treatment, focus on what’s approved now, and check back on EloraTZP when AMPLIFY results land.
So tell me: would a “Zepbound plus amylin” shot be worth waiting until 2030 for, or would you rather start something now?
MealCoach